MA54383A - Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique - Google Patents
Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophiqueInfo
- Publication number
- MA54383A MA54383A MA054383A MA54383A MA54383A MA 54383 A MA54383 A MA 54383A MA 054383 A MA054383 A MA 054383A MA 54383 A MA54383 A MA 54383A MA 54383 A MA54383 A MA 54383A
- Authority
- MA
- Morocco
- Prior art keywords
- neurofilamentous
- protein
- lateral sclerosis
- amyotrophic lateral
- therapeutic intervention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862776253P | 2018-12-06 | 2018-12-06 | |
US201962840431P | 2019-04-30 | 2019-04-30 | |
US201962842063P | 2019-05-02 | 2019-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54383A true MA54383A (fr) | 2021-10-13 |
Family
ID=68966114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054383A MA54383A (fr) | 2018-12-06 | 2019-12-03 | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220034907A1 (fr) |
EP (1) | EP3890752A1 (fr) |
JP (1) | JP2022513721A (fr) |
KR (1) | KR20210102294A (fr) |
CN (1) | CN113365640A (fr) |
BR (1) | BR112021010660A2 (fr) |
CA (1) | CA3121749A1 (fr) |
MA (1) | MA54383A (fr) |
MX (1) | MX2021006548A (fr) |
WO (1) | WO2020117772A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021511389A (ja) | 2018-01-25 | 2021-05-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 脊髄性筋萎縮症を治療する方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050019915A1 (en) * | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
CA2790034A1 (fr) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Modulation anti-sens de l'expression de la superoxyde dismutase 1 soluble |
US9096543B2 (en) | 2012-05-09 | 2015-08-04 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
WO2014062736A1 (fr) | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Procédés permettant de surveiller l'expression de c9orf72 |
JP6570447B2 (ja) | 2012-10-15 | 2019-09-04 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | C9orf72発現を調節するための組成物 |
US9963699B2 (en) | 2012-10-15 | 2018-05-08 | Ionis Pharmaceuticals, Inc. | Methods for modulating C9ORF72 expression |
CN104853778A (zh) * | 2012-10-24 | 2015-08-19 | 第一三共株式会社 | 用于肌萎缩性侧索硬化的治疗剂 |
AU2014331652B2 (en) | 2013-10-11 | 2020-05-21 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
WO2015057727A1 (fr) | 2013-10-14 | 2015-04-23 | Isis Pharmaceuticals, Inc. | Compositions destinées à moduler l'expression du transcrit antisens c9orf72 |
AU2014337506B2 (en) | 2013-10-14 | 2020-10-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of C9ORF72 antisense transcript |
WO2015143245A1 (fr) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Méthodes pour moduler l'expression de l'ataxine 2 |
JP6902869B2 (ja) | 2014-03-19 | 2021-07-14 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | アタキシン2の発現を調節するための組成物 |
SG11201608109TA (en) | 2014-04-01 | 2016-10-28 | Ionis Pharmaceuticals Inc | Compositions for modulating sod-1 expression |
AU2015326911B2 (en) | 2014-09-30 | 2021-07-08 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (DPRs) antibody |
AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US10793855B2 (en) | 2015-01-06 | 2020-10-06 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
SG11201708468YA (en) | 2015-04-16 | 2017-11-29 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
WO2017079291A1 (fr) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Composés et méthodes de modulation de c90rf72 |
WO2017117496A1 (fr) | 2015-12-31 | 2017-07-06 | Ionis Pharmaceuticals, Inc. | Méthodes pour diminuer l'expression de l'ataxine-2 |
AU2017248637A1 (en) | 2016-04-13 | 2018-09-27 | Ionis Pharmaceuticals, Inc. | Methods for reducing C9ORF72 expression |
AU2018316159A1 (en) | 2017-08-08 | 2020-02-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
KR20210018807A (ko) | 2018-04-27 | 2021-02-18 | 바이오젠 엠에이 인코포레이티드 | 인간-유래 항-(폴리-ga) 디펩타이드 반복 (dpr) 항체 |
-
2019
- 2019-12-03 JP JP2021531983A patent/JP2022513721A/ja active Pending
- 2019-12-03 CN CN201980080522.8A patent/CN113365640A/zh active Pending
- 2019-12-03 WO PCT/US2019/064190 patent/WO2020117772A1/fr unknown
- 2019-12-03 EP EP19824179.6A patent/EP3890752A1/fr active Pending
- 2019-12-03 BR BR112021010660-0A patent/BR112021010660A2/pt unknown
- 2019-12-03 US US17/299,660 patent/US20220034907A1/en active Pending
- 2019-12-03 CA CA3121749A patent/CA3121749A1/fr active Pending
- 2019-12-03 MA MA054383A patent/MA54383A/fr unknown
- 2019-12-03 MX MX2021006548A patent/MX2021006548A/es unknown
- 2019-12-03 KR KR1020217020744A patent/KR20210102294A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
CA3121749A1 (fr) | 2020-06-11 |
BR112021010660A2 (pt) | 2021-08-24 |
KR20210102294A (ko) | 2021-08-19 |
CN113365640A (zh) | 2021-09-07 |
US20220034907A1 (en) | 2022-02-03 |
JP2022513721A (ja) | 2022-02-09 |
EP3890752A1 (fr) | 2021-10-13 |
WO2020117772A1 (fr) | 2020-06-11 |
MX2021006548A (es) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA52010A (fr) | Administration intracellulaire de biomolécules pour modifier une réponse immunitaire | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA44146A (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
MA43587A (fr) | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 | |
MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
MA52801A (fr) | Conjugués oligomères à saut d'exon pour dystrophie musculaire | |
MA52657A (fr) | Anticorps spécifiques d'axl pour le traitement du cancer | |
FR3043925B1 (fr) | Formage d'un coude dans une ondulation | |
MA44378A (fr) | Protéines de fusion immunogènes pour le traitement du cancer | |
MA47502A (fr) | Combinaisons pharmaceutiques pour traiter le cancer | |
MA46999A (fr) | Oligonucléotides modifiés pour traiter la polykystose rénale | |
MA52499A (fr) | Associations pour le traitement du cancer | |
MA54383A (fr) | Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique | |
MA54559A (fr) | Polythérapie pour le traitement du cancer | |
FR3041237B1 (fr) | Systeme pour le traitement d'une epistaxis | |
FR3035403B1 (fr) | Utilisation d'acide alcane sulfonique pour le nettoyage dans les industries sucrieres | |
KR20220035365A (ko) | 인터페론의 부작용을 감소시키는 방법 | |
MA53436A (fr) | Anticorps anti-cgrp pour patients résistants au traitement | |
MA47474A (fr) | Polythérapie rationelle pour le traitement du cancer | |
MA50891A (fr) | Triterpènes pentacycliques dans le traitement d'une pathologie bucco-dentaire |